Loading
ET
Edap TMS SA Stock: price and insider trades · United States
8 insiders bought €477k of shares over the last 90 days, the latest filed 17 Aug 2026.
Edap TMS SA: what insiders have been doing
Every trade that managers of Edap TMS SA disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 9 filings signed by 8 insiders.
Every open-market trade in the period is a purchase: 8 purchases worth €477k, from 8 insiders, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 6 senior executives, 1 finance chief and 1 chief executive among the declarants. Biggest ticket of the year: €206k, bought by Willsey Lance and made public on 17 August 2026 (0.14% of market cap).
Within a 30-day window, 8 purchases overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 17 August 2026, 62 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,811 companies) published 19 filings over the same period, against 9 filings here. The full history, which starts in 2026, counts 8 purchases against no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
9
Thresholds
n/a
Buy Volume
€477,441
8 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleDavid R. Horn1 buy
Fran Schulz1 buy
Joshua Levine1 buy
Kenneth S. Mobeck1 buy
Lance Willsey1 buy
Ryan Rhodes1 buy
+2 other insiders
Since the insiders bought
- +0.5%Entry US$4.26 · Close at T+30 US$4.28
- +0.5%Entry US$4.26 · Close at T+30 US$4.28
- +0.5%Entry US$4.26 · Close at T+30 US$4.28
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Edap TMS SA Buy (bullish), based on 5 analysts. Average price target: US$8.80.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,584 of 24,148 companies
18.0
score / 100
Value14
Quality22
FCF yld-11%
Earn yld-15%
EV/EBITDA·
ROE-266%
Gross mgn43%
Net mgn-41%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.99
Analyst consensus
5 analystsBuy
US$4.00Target US$8.80(+121%)US$15.00
Income statement
RevenueUS$70.5M
Gross profitUS$30M43% margin
EBITDA-US$24.6M-35% margin
Net income-US$29.2M-49.1% margin
Valuation
PER (forward)-6.0x
P/Book8.3x
Beta-0.05
Balance sheet & cash
Market capUS$188.4M
Total debtUS$27.7M
Free Cash Flow-US$22.2M
Debt / Equity275%
Profitability & ownership
ROE-265.7%
ROA-22.1%
% insiders5.1%
% institutions32.2%
Last declaration on 17 August 2026
Declarations9 total
5,000 shares@ US$4.750.014% mcap100.0% of flowCommon StockSEC:0001829126-26-008920:0
Canonical exit: 12 Nov 2026 (T+90)
5,000 shares@ US$4.750.014% mcap100.0% of flowCommon StockSEC:0001829126-26-008921:0
Canonical exit: 12 Nov 2026 (T+90)
21,000 shares@ US$4.750.061% mcap100.0% of flowCommon StockSEC:0001829126-26-008922:0
Canonical exit: 12 Nov 2026 (T+90)
50,000 shares@ US$4.750.14% mcap100.0% of flowCommon StockSEC:0001829126-26-008923:0
Canonical exit: 12 Nov 2026 (T+90)
10,000 shares@ US$4.750.029% mcap100.0% of flowCommon StockSEC:0001829126-26-008927:0
Canonical exit: 12 Nov 2026 (T+90)
5,000 shares@ US$4.750.014% mcap100.0% of flowCommon StockSEC:0001829126-26-008924:0
Canonical exit: 12 Nov 2026 (T+90)
10,000 shares@ US$4.750.029% mcap100.0% of flowCommon StockSEC:0001829126-26-008925:0
Canonical exit: 12 Nov 2026 (T+90)
10,000 shares@ US$4.750.029% mcap100.0% of flowCommon StockSEC:0001829126-26-008926:0
Canonical exit: 12 Nov 2026 (T+90)
67,500 shares0Common StockSEC:0001829126-26-005047:0
9 of 9 declarations
About Edap TMS SA
Edap TMS SA is a French medical device company focused on minimally invasive ultrasound-based therapies. The company is listed on the Nasdaq in the United States, making it relevant for U.S. equity investors even though its corporate roots and headquarters are in Vaulx-en-Velin, near Lyon, France. Founded in 1979, EDAP has built its business over several decades around therapeutic ultrasound and urology, gradually sharpening its strategic focus toward higher-value robotic energy-based therapies.
The company’s core investment thesis is now centered on Focal One®, its robotic High-Intensity Focused Ultrasound (HIFU) platform for prostate tissue ablation. Focal One integrates imaging, robotics, and precise non-invasive energy delivery to target tissue without open surgery. That positions EDAP as a niche but important player in focal therapy for prostate cancer, a market where physicians are looking for less invasive options that may preserve quality-of-life outcomes relative to traditional radical procedures. This is where EDAP differentiates itself: not as a broad medtech conglomerate, but as a specialized technology company with a clinically oriented platform and a focused commercial message.
Read moreShow less
EDAP still maintains legacy or non-core activities, including extracorporeal shock wave lithotripsy (ESWL) systems for urinary stones and certain third-party product distribution businesses. However, management has clearly been prioritizing HIFU as the main growth engine. The company’s international footprint includes direct operations and commercialization in the United States, Europe, and select other markets, supported by a commercial and clinical network that helps drive system placements and recurring disposables revenue.
Recent developments have reinforced that strategic direction. In 2025, EDAP launched Focal One i, a next-generation robotic HIFU system, and continued to report clinical and commercial progress in the U.S. market. In March 2026, the company reported record fourth-quarter and full-year 2025 HIFU revenue, highlighted continued growth in Focal One system placements and U.S. procedures, and reiterated 2026 guidance pointing to further expansion of the core HIFU business. For investors, EDAP remains a specialized growth story in medical technology, with key watchpoints including procedure adoption, regulatory milestones, reimbursement dynamics, and the pace of commercial scaling in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
